Biopharma Stock Updates - 12/10/20

Data Updates:

$BNTX (+3.66%) - Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine

$MRNA (+1.00%) - First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine

$RGNX - (+2.83%) - Dosing Of First Patient In Phase II ALTITUDE™ Trial Of RGX-314 For The Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery

$SPRO (-1.03%) - First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

$TGTX (+22.28%) - Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis


$KALV (+0.50%) - Reports Second Fiscal Quarter Results

$NLTX (+1.17%) - Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer

$PTGX (-11.37%) –Public offering of$100,000,000 of shares of its common stock


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.